This activity is part 2 in a 3-part webinar curriculum.
Program Description
Heart failure (HF) is associated with dysfunction in a number of pathways, including impaired synthesis of nitric oxide and decreased activity of soluble guanylate cyclase. While a range of therapies is available, each requires specific patient education and monitoring considerations for long-term cardiovascular management. This webinar will focus on the role of soluble guanylate stimulators in the management of HF and clinical data supporting the use of these agents in reducing hospitalizations in patients with HF with reduced ejection fraction. Considerations for the administration and dosing of soluble guanylate stimulators as well as their place in guideline-directed medical therapy for patients with HF will be reviewed.
Target audience: Health-system and retail pharmacists
Type of activity: Application
Release date: August 24, 2023
Expiration date: October 24, 2023
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore updates to the guideline recommendations for management of worsening heart failure with reduced ejection fraction (HFrEF)
- Examine the mechanism of action of soluble guanylate cyclase stimulators and their potential benefits in the management of worsening HFrEF
- Analyze the clinical trial data associated with the use of soluble guanylate cyclase stimulators and their dosing and administration
Jared Sheley, PharmD, BCPS
Clinical Associate Professor
Department of Pharmacy Practice
Southern Illinois University Edwardsville School of Pharmacy
Edwardsville, Illinois
Clinical Pharmacy Specialist, Internal Medicine
HSHS St. Elizabeth's Hospital
O'Fallon, Illinois
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-316-L01-P. The activity is available for CE credit through October 24, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Jared Sheley, PharmD, BCPS
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms